Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: Assessment of pharmacokinetic changes and safety following single and multipe oral doses

British Journal of Clinical Pharmacology, Supplement

Volumn 58, Issue 1, 2004, Pages 25-33

  Nagy, Christa F ^a   Kumar, Dinesh ^a   Perdomo, Carlos A ^a   Wason, Suman ^b,c   Cullen, Edward I ^a,d   Pratt, Raymond D ^a  

^a EISAI INC   (United States)

^b Department of Pharmacokinetics and Scientific Affairs   (United States)

^c PFIZER INC   (United States)

^d Shire Pharmaceutical Devmt Inc ^*

Author keywords

Acetylcholinesterase inhibitor; Alzheimer's disease; Donepezil; Drug drug interaction; Pharmacokinetics; Sertraline

Indexed keywords

AMOXICILLIN; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CLARITHROMYCIN; DONEPEZIL; GUAIFENESIN; IBUPROFEN; NON PRESCRIPTION DRUG; SERTRALINE;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; EOSINOPHILIA; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INSOMNIA; LUNG TOXICITY; MALE; MASS SPECTROMETRY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROTOXICITY; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STEADY STATE; STOMACH PAIN; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; ALZHEIMER DISEASE; CLINICAL ARTICLE; DRUG RESPONSE; MULTIPLE DRUG DOSE; SINGLE DRUG DOSE; STOMACH DISEASE;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS; CHOLINESTERASE INHIBITORS; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; INDANS; MALE; MIDDLE AGED; PIPERIDINES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 8844247125     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978; 2: 1457-9.
2. Lawrence AD, Sahakian BJ. Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord 1995; 9(Suppl. 2): 43-9.
3. ARICEPT® (donepezil hydrochloride tablets). US package insert, December 2000. Teaneck, NJ: Eisai Inc.
4. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-44.
5. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44.
6. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P; Donepezil Nordic Study Group. A 1-year randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95.
7. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD; "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8.
8. Rogers SL, Friedhoff LT. Pharmacokinetic and pharamacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 1-6.
9. Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 7-12.
10. 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 1998; 46(Suppl. 1): 19-24.
11. Tiseo PJ, Perdomo CA, Friedhoff LT, Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 25-9.
12. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46(Suppl. 1): 30-4.
13. Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996; 153: 1438-43.
14. Migliorelli R, Teson A, Sabe L, Petrachi M, Leiguarda R, Starkstein SE. Prevalence and correlates of dysthymia and major depression among patients with Alzheimer's disease. Am J Psychiatry 1995; 152: 37-44.
15. Teri L, Wagner A. Alzheimer's disease and depression. J Consult Clin Psychol 1992; 60: 379-91.
16. McRae T, Orazem J. A large-scale, open-label trial of donepezil in the treatment of Alzheimer's disease: side-effects and concomitant medication use. Int J Neuropsychopharmacol 1999; 2(Suppl. 1): S176.
17. Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49: 1590-9.
18. Lyketsos CG, Sheppard JM, Steele CD, Kopunek S, Steinberg M, Baker AS, Brandt J, Rabins PV. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the depression in Alzheimer's disease study. Am J Psychiatry 2000; 157: 1686-9.
19. McRae T, Griesing T, Whalen E. Managing behavioural symptoms in patients with Alzheimer's disease. J Am Geriatr Soc 2000; 48(Suppl. 8): S109.
20. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders - I. Basic Pharmacology. J Psychopharmacol 1998; 12(Suppl. B): S5-S20.
21. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991; 6(Suppl. 2): 11-2.
22. Height and Weight Standards. New York: Metropolitan Life Insurance Company, 1983.
23. Zoloft® (sertraline hydrochloride) tablets and oral concentrate. US package insert, May 2002. New York, NY: Pfizer Inc.
24. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL, Mendels J. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51: 18-27.
25. US Food and Drug Administration. COSTART: Coding Symbol Thesaurus for Adverse Reaction Terms, 3rd edn. Rockville, MD: Center for Drugs and Biologics, Division of Drug and Biological Products Experience, 1989.
26. Janicak PG, Davis JM, Preskorn SH, Ayd Jr. FJ. Principles and Practice of Psychopharmacotherapy. Baltimore, MD: Williams & Wilkins, 1993.
27. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effects of selective serotonin reuptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-5.
28. Ball SE, Ahern D, Scatina J, Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRI, and effects on human CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997; 43: 619-26
29. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz J, Wright CE, Shader RI. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996; 16: 104-12.
30. Ring BJ, Binkley SN, Roskos L, Wrighton SA. Effects of fluoxetine, norfluoxetine, sertraline and desmethylsertraline on human CYP3A catalyzed l'hydroxymidazolam formation in vitro. J Pharmacol Exp Ther 1995; 275: 1131-5.
31. Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999; 27: 763-6.
32. Sproule BA, Otton SV, Cheung SW, Zhong XH, Romach MK, Sellers EM. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997; 17: 102-6.
33. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol 1996; 16: 267-72.
34. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998; 46(Suppl. 1): 40-4.
35. Tiseo PJ, Perdomo CA, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998; 46(Suppl. 1): 45-50
36. Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 1998; 6(Suppl. 1): 35-9.
37. McRae T, Griesing T, Whalen E. Effectiveness of donepezil on behavioral disturbances in mild to moderate Alzheimer's disease patients. Neurobiol Aging 2000; 21(Suppl. 1): S93.
38. Dewan MJ, Anand VS. Evaluating the tolerability of newer antidepressants. J Nerv Ment Dis 1999; 187: 96-101.
39. Finkel SI, Richter EM, Clary CM. Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older, Int Psychogeriatr 1999; 11: 85-9.